BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.
BRCA1
BRCA2
attitudes
bilateral salpingo-oophorectomy
disparities
genetic counseling
genetic testing
hereditary breast and ovarian cancer
risk management
underrepresented populations
Journal
Journal of genetic counseling
ISSN: 1573-3599
Titre abrégé: J Genet Couns
Pays: United States
ID NLM: 9206865
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
27
07
2020
received:
05
03
2020
accepted:
06
08
2020
pubmed:
4
10
2020
medline:
16
10
2021
entrez:
3
10
2020
Statut:
ppublish
Résumé
Bilateral salpingo-oophorectomy (BSO) is a risk management approach with strong evidence of mortality reduction for women with germline mutations in the tumor suppressor genes BRCA1 and BRCA2 (BRCA1/2). Few studies to date have evaluated uptake of BSO in women from diverse racial and ethnic backgrounds who carry BRCA1/2 mutations. The objective of the UPTAKE study was to explore rates and predictors of risk-reducing BSO among Latinas affected and unaffected with breast cancer who had a deleterious BRCA1/2 mutation. We recruited 100 Latina women with deleterious BRCA1/2 mutations from community hospitals, academic health systems, community, and advocacy organizations. Women completed interviews in Spanish or English. We obtained copies of genetic test reports for participants who provided signed medical release. After performing threefold cross-validation LASSO for variable selection, we used multiple logistic regression to identify demographic and clinical predictors of BSO. Among 100 participants, 68 had undergone BSO at the time of interview. Of these 68, 35 were US-born (61% of all US-born participants) and 33 were not (77% of the non-US-born participants). Among Latinas with BRCA1/2 mutations, older age (p = 0.004), personal history of breast cancer (p = 0.003), higher income (p = 0.002), and not having a full-time job (p = 0.027) were identified as variables significantly associated with uptake of BSO. Results suggest a high rate of uptake of risk-reducing BSO among a sample of Latinas with BRCA1/2 mutations living in the US. We document factors associated with BSO uptake in a diverse sample of women. Relevant to genetic counseling, our findings identify possible targets for supporting Latinas' decision-making about BSO following receipt of a positive BRCA1/2 test.
Identifiants
pubmed: 33010199
doi: 10.1002/jgc4.1322
pmc: PMC10064975
mid: NIHMS1878513
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-393Subventions
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NCI NIH HHS
ID : GR 411788
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA051008
Pays : United States
Informations de copyright
© 2020 National Society of Genetic Counselors.
Références
Cancer. 2012 Jan 15;118(2):510-7
pubmed: 21717445
JAMA. 2010 Sep 1;304(9):967-75
pubmed: 20810374
Genet Test Mol Biomarkers. 2010 Feb;14(1):99-106
pubmed: 19929403
Breast Cancer Res Treat. 2015 Jan;149(1):223-7
pubmed: 25476495
J Clin Oncol. 2005 Oct 20;23(30):7491-6
pubmed: 16234515
N Engl J Med. 1997 May 15;336(20):1401-8
pubmed: 9145676
J Natl Cancer Inst. 2013 Jun 5;105(11):812-22
pubmed: 23628597
BMC Public Health. 2010 Aug 13;10:481
pubmed: 20707902
N Engl J Med. 2002 May 23;346(21):1609-15
pubmed: 12023992
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558
Cancers (Basel). 2018 Nov 02;10(11):
pubmed: 30400234
Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):498-505
pubmed: 25371446
Int J Cancer. 2008 May 1;122(9):2017-22
pubmed: 18196574
Clin Cancer Res. 2016 Aug 1;22(15):3971-81
pubmed: 26979395
Genet Med. 2008 Mar;10(3):161-166
pubmed: 18344704
J Natl Cancer Inst. 1999 Sep 1;91(17):1475-9
pubmed: 10469748
J Clin Oncol. 2015 May 10;33(14):1584-91
pubmed: 25847940
J Clin Oncol. 2007 Apr 10;25(11):1329-33
pubmed: 17416853
Ann Oncol. 2016 Sep;27(suppl 5):v103-v110
pubmed: 27664246
J Clin Oncol. 2014 May 20;32(15):1547-53
pubmed: 24567435
Cancer. 2015 Feb 1;121(3):372-8
pubmed: 25236687
Hum Mutat. 2016 Jun;37(6):564-9
pubmed: 26931183
Br J Cancer. 2019 Jul;121(1):15-21
pubmed: 30971774
J Clin Oncol. 2013 Jan 10;31(2):210-6
pubmed: 23233716
Cochrane Database Syst Rev. 2018 Apr 05;4:CD002748
pubmed: 29620792
Am J Surg. 2016 Oct;212(4):660-669
pubmed: 27649974
Cancer Causes Control. 2008 Dec;19(10):1373-82
pubmed: 18704716
Cancer. 2017 Jul 1;123(13):2497-2505
pubmed: 28182268
Breast J. 2006 May-Jun;12(3):221-32
pubmed: 16684320
Breast Cancer Res Treat. 2015 Dec;154(3):441-53
pubmed: 26564481
Am J Cancer Res. 2014 Dec 15;5(1):466-71
pubmed: 25628955
Hum Mutat. 2003 Apr;21(4):448
pubmed: 12655567
Gynecol Oncol. 2015 Jan;136(1):3-7
pubmed: 25238946
Obstet Gynecol. 2017 Sep;130(3):e110-e126
pubmed: 28832484